Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)
The Clinical Respiratory Journal · 2023
DOI: 10.1111/crj.13715 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2023. Verfasst von Bo Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Anti-Cancer Association.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Durvalumab is a check‐point inhibitor against programmed death ligand‐1 (PD‐L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical and clinical trials have suggested that antiangiogenic therapy has the potential to alleviate immunosuppression and showed synergetic effect when combined with ICIs. However, it is unclear that whether this combination is effective when initiated as maintenance treatment in ES‐SCLC patients.
Methods
This is a multicenter, randomized, phase II study. A total of 64 eligible patients who do not experience disease progression after four cycles platinum‐based chemotherapy combined with durvalumab will be randomized to durvalumab with anlotinib or durvalumab alone until disease progression, withdrawal of consent, or unacceptable toxicity. The primary endpoint is PFS (from randomization); secondary endpoint was OS and PFS (from diagnosis), objective response rate (ORR); disease control rate (DCR) and duration of response (DOR), safety and tolerability assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Discussion
We conduct a phase II study to investigate the safety and efficacy of durvalumab combined with anlotinib as maintenance treatment in ES‐SCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Runbo Zhong, Baohui Han
Förderung
- Shanghai Anti-Cancer Association
Zitieren
APA
Zhang, B., Zhong, H., Shi, C., Gao, Z., Zhong, R., Gu, A., Wang, W., Chu, T., Xiong, L., Zhang, W., Wang, H., Zhang, X., & Han, B. (2023). Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study). The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13715
Vancouver
Zhang B, Zhong H, Shi C, Gao Z, Zhong R, Gu A, et al. Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study). The Clinical Respiratory Journal. 2023. doi:10.1111/crj.13715
BibTeX
@article{Zhang2023,
author = {Zhang, Bo and Zhong, Hua and Shi, Chunlei and Gao, Zhiqiang and Zhong, Runbo and Gu, Aiqin and Wang, Weimin and Chu, Tianqing and Xiong, Liwen and Zhang, Wei and Wang, Huimin and Zhang, Xueyan and Han, Baohui},
title = {Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)},
journal = {The Clinical Respiratory Journal},
year = {2023},
doi = {10.1111/crj.13715}
}
EUVIMED